#

Biotechnology

: 158
Definium went public in 2025 as MindMed, after which, in January 2026, it changed its name / Photo: X/Definium Therapeutics
Small Caps·
Biotech Definium reports another phase III success for anxiety disorder therapy
Ad campaigns featuring movie and sports stars have boosted American Eagles brand recognition / Photo: Zoltan Tarlacz / Shutterstock.com
Small Caps·
Small caps last week: Chewy's earnings miss, Signet's best day ever, AE rethinks ads
Anthropic reported that it had thwarted attempts to use AI models to create biological weapons / Photo: gguy / Shutterstock.com
News·
Anthropic discussed attempts to use AI to develop biological weapons
Wells Fargo cited macroeconomic headwinds for Canada Goose including El Niño weather patterns, challenges in Europe, the Middle East and Africa, and tariffs / Photo: kaskip / Shutterstock.com
Small Caps·
Small caps last week: Canada Goose downgrade, smart glasses rollout, Volato AI pivot
BioNTech and Roche have halted trials of an experimental personalized mRNA immunotherapy for patients with stage II–III colorectal cancer / Photo: Kittyfly / Shutterstock.com
News·
BioNTech and Roche have halted a cancer vaccine trial. What does this mean for the industry?
TD Cowen reckons that the current year is critical in establishing the market presence of UroGens bladder cancer drug, with sales of $120-150 million expected / Photo: Shutterstock.com
Small Caps·
UroGen: The mid-cap bladder cancer biotech that is TD Cowen's top sector pick in 2026
The Japanese pharmaceutical company Takeda is ready to launch a revolutionary drug for the treatment of sleep disorders. Photo: Solving Healthcare/Unsplash.com
Review·
Orexins—the Next Ozempic? The Pharmaceutical Industry Prepares for a Breakthrough in Neuroscience
Photo: Andrei Doronichevs personal archive.
Review·
Five biotech companies that Andrei Doronichev is keeping an eye on
Modernas 177% stock surge led to multibillion-dollar paper losses for short sellers / Photo: Shutterstock.com / Tada Images
News·
Moderna's stock price nearly tripled, resulting in $5.5 billion in paper losses for short sellers
Amylyx Pharmaceuticals surged after its drug candidate, avexitide, met primary and secondary endpoints in a phase III clinical trial / Photo: Unsplash/Julia Koblitz
Small Caps·
Mid-cap biotech Amylyx jumps 60% after drug meets endpoints in late-stage trial
Andrey Doronichevs startup, Bioptic, is currently raising a new round of funding / Photo: Evgenia Eliseeva / Andrey Doronichevs personal archive
News·
Andrey Doronichev's biotech startup, Bioptic, is considering an IPO
Photo: Evgenia Eliseeva / Andrei Doronichevs personal archive
Review·
'New leaders will rise from the ashes': An interview with Andrey Doronichev
Load more